Risk of Adverse Outcomes in Females Taking Oral Creatine Monohydrate: A Systematic Review and Meta-Analysis
de Guingand DL, Palmer KR, Snow RJ, Davies-Tuck ML, Ellery SJ
Nutrients · 24 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Monash University
- Gobierno
- State Government of Victoria
- Universidad u hospital
- Hudson Institute of Medical Research
- Gobierno
- National Health and Medical Research Council
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2020-06-15 · Nutrients · vol. 12 · número 6 · pág. 1780
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 36 citas · más que el 57% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 196 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Muscle metabolism and nutrition · Pharmacology and Obesity Treatment · Dietetics, Nutrition, and Education
- Palabras clave
- Adverse effect, Medicine, Creatine, Meta-analysis, Internal medicine, Relative risk, Confidence interval
- MeSH
- humans, gastrointestinal diseases, liver diseases, weight gain, creatine, risk assessment, body composition, dietary supplements, adult, aged, middle aged, female, young adult
5 autores
- Deborah L. de Guingand🇦🇺 · autor de correspondenciaHudson Institute of Medical Research
- Kirsten Rebecca Palmer🇦🇺Monash Medical Centre; Monash Health; Monash University
- Rodney J. Snow🇦🇺Deakin University
- Miranda L. Davies-Tuck🇦🇺Hudson Institute of Medical Research
- Stacey J. Ellery🇦🇺Hudson Institute of Medical Research; Monash University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Creatine Monohydrate (CrM) is a dietary supplement routinely used as an ergogenic aid for sport and training, and as a potential therapeutic aid to augment different disease processes. Despite its increased use in recent years, studies reporting potential adverse outcomes of CrM have been mostly derived from male or mixed sex populations. A systematic search was conducted, which included female participants on CrM, where adverse outcomes were reported, with meta-analysis performed where appropriate. Six hundred and fifty-six studies were identified where creatine supplementation was the primary intervention; fifty-eight were female only studies (9%). Twenty-nine studies monitored for adverse outcomes, with 951 participants. There were no deaths or serious adverse outcomes reported. There were no significant differences in total adverse events, (risk ratio (RR) 1.24 (95% CI 0.51, 2.98)), gastrointestinal events, (RR 1.09 (95% CI 0.53, 2.24)), or weight gain, (mean difference (MD) 1.24 kg pre-intervention, (95% CI -0.34, 2.82)) to 1.37 kg post-intervention (95% CI -0.50, 3.23)), in CrM supplemented females, when stratified by dosing regimen and subject to meta-analysis. No statistically significant difference was reported in measures of renal or hepatic function. In conclusion, mortality and serious adverse events are not associated with CrM supplementation in females. Nor does the use of creatine supplementation increase the risk of total adverse outcomes, weight gain or renal and hepatic complications in females. However, all future studies of creatine supplementation in females should consider surveillance and comprehensive reporting of adverse outcomes to better inform participants and health professionals involved in future trials.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.